List of Excipients in Branded Drug FINACEA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Intendis Inc	FINACEA	azelaic acid	10922-825	1,2-DIARACHIDOYL-SN-GLYCERO-3-PHOSPHOCHOLINE
Intendis Inc	FINACEA	azelaic acid	10922-825	BENZOIC ACID
Intendis Inc	FINACEA	azelaic acid	10922-825	EDETATE DISODIUM
Intendis Inc	FINACEA	azelaic acid	10922-825	MEDIUM-CHAIN TRIGLYCERIDES
Intendis Inc	FINACEA	azelaic acid	10922-825	POLYACRYLIC ACID
Intendis Inc	FINACEA	azelaic acid	10922-825	POLYSORBATE 80
Intendis Inc	FINACEA	azelaic acid	10922-825	PROPYLENE GLYCOL

Finacea Excipient Strategy and Commercial Opportunities for Azelaic Acid Products

Last updated: August 18, 2026

Finacea is a prescription topical azelaic acid product with two U.S. dosage forms: a 15% gel and a 15% foam. The active ingredient is an established small molecule with no biosimilar exposure and limited active-ingredient exclusivity. The principal commercial opportunity is therefore vehicle differentiation: improving spreadability, skin feel, tolerability, delivery, packaging, and manufacturing efficiency while preserving pharmaceutical equivalence and clinical performance.

The most attractive development targets are generic or follow-on products that reproduce the Finacea gel or foam performance profile, along with differentiated azelaic acid vehicles for acne, rosacea, post-inflammatory hyperpigmentation, and other dermatologic uses.

What is Finacea and which dosage forms are commercially relevant?

Finacea contains azelaic acid at a concentration of 15%. The U.S. products are:

Product	Dosage form	Strength	Primary FDA-labeled use	Commercial relevance
Finacea Gel	Topical gel	15%	Inflammatory papules and pustules of mild-to-moderate rosacea	More accessible generic-development target
Finacea Foam	Topical foam	15%	Inflammatory papules and pustules of mild-to-moderate rosacea	Higher formulation and packaging complexity
Azelaic acid products outside the U.S.	Cream, gel, suspension, foam, cosmetic formulations	Commonly 10%-20%	Acne, pigmentation, rosacea and cosmetic skin concerns	Broad private-label and geographic opportunity

Finacea Gel is an aqueous semisolid system using azelaic acid with carbomer, lecithin, polysorbate 20, propylene glycol, triglycerides, sodium hydroxide, edetate disodium, benzoic acid, and purified water. Finacea Foam uses a different architecture based on fatty alcohols, glyceryl stearate, glycerol, polysorbate 60, potassium sorbate, citric acid, purified water, and a hydrocarbon propellant system (FDA, 2023a; FDA, 2023b).

The products are commercially distinct even though they contain the same active ingredient and strength. The gel is a conventional semisolid formulation. The foam requires control of emulsion structure, propellant behavior, container compatibility, product discharge, collapse time, and in-use application properties.

What excipients are used in Finacea Gel?

Finacea Gel uses excipients that address azelaic acid’s formulation challenges, including low aqueous solubility, particle dispersion, pH control, preservation, and topical feel.

Excipient or excipient class	Likely formulation role
Carbomer 934P	Gelling agent and rheology modifier
Sodium hydroxide	Neutralization and pH adjustment of carbomer
Propylene glycol	Humectant, cosolvent and skin-feel modifier
Lecithin	Emulsification, dispersion and skin-conditioning function
Polysorbate 20	Surfactant and dispersion aid
Triglycerides	Emollient and vehicle component
Edetate disodium	Chelating agent supporting preservative and stability performance
Benzoic acid	Antimicrobial preservative
Purified water	Continuous phase

The excipient strategy is conservative and compatible with a conventional topical gel. Carbomer provides viscosity and suspension support, while sodium hydroxide controls neutralization and rheology. Propylene glycol can improve wetting and application but may contribute to stinging or irritation in sensitive skin. Surfactants and lecithin support dispersion but can affect sensory properties and irritation potential.

A generic developer does not need to duplicate every qualitative or quantitative excipient detail in all circumstances. It must, however, demonstrate that differences do not affect safety, effectiveness, quality, or performance. For a topical semisolid, the practical development target is usually a close match in critical quality attributes rather than a simple ingredient-list comparison.

What excipients are used in Finacea Foam?

Finacea Foam uses a lipid-based foam system with fatty alcohols, an emulsifier, humectant, preservative, aqueous phase, and hydrocarbon propellant.

Excipient or excipient class	Likely formulation role
Cetyl alcohol	Structuring agent, emollient and consistency modifier
Stearyl alcohol	Structuring agent and emollient
Glyceryl stearate	Emulsifier and consistency agent
Polysorbate 60	Surfactant and emulsion stabilizer
Glycerol	Humectant
Citric acid	pH adjustment and buffering support
Potassium sorbate	Preservative
Isobutane	Propellant
Purified water	Aqueous phase

The foam vehicle creates more development risk than the gel because the formulation and package are interdependent. The same bulk formula can produce materially different patient experiences depending on valve design, actuator geometry, fill weight, propellant ratio, canister pressure, storage conditions, and dispensing orientation.

Commercial developers should treat Finacea Foam as a combination of formulation and delivery system. Excipient substitution without matching foam density, particle or droplet distribution, collapse behavior, discharge rate, and residue can create regulatory and market-acceptance problems.

What excipient strategy is most attractive for Finacea generic development?

The strongest strategy depends on the reference product.

Finacea Gel strategy

A generic gel developer should prioritize:

1. Matching azelaic acid particle size and dispersion.
2. Controlling pH to preserve tolerability and rheology.
3. Reproducing viscosity across shear rates and temperature conditions.
4. Managing preservative effectiveness and microbial quality.
5. Reducing tackiness and residue without compromising drug release.
6. Using widely accepted topical excipients with established regulatory precedent.

Potential formulation improvements include lower-irritancy humectant systems, optimized carbomer grades, alternative nonionic surfactants, and improved emollient blends. These changes can support a superior sensory profile, but they may also alter drug release, skin permeation, or local tolerability.

Finacea Foam strategy

A foam developer should prioritize:

1. Foam stability over the labeled shelf life.
2. Consistent discharge from the first dose to the last.
3. Controlled evaporation and collapse after application.
4. Low residue and rapid absorption.
5. Compatibility between formulation, propellant, valve, actuator, and canister.
6. Robust performance under temperature and shipping variation.

The most defensible improvements are often package and process improvements rather than aggressive excipient changes. A developer may seek better dose consistency, lower residual pressure, improved valve performance, or a more stable emulsion while retaining the basic excipient architecture.

What formulation patents protect Finacea?

Finacea’s commercial protection has historically related more to the dosage form, formulation, use, and delivery system than to azelaic acid itself. Azelaic acid is an old, well-characterized compound, so its composition-of-matter protection is not commercially relevant for current U.S. products.

Potentially relevant protection categories include:

Protection category	Relevance to Finacea
Azelaic acid composition patents	Low current relevance because the molecule is long established
Gel formulation patents	May cover excipient combinations, concentration, pH, rheology or use
Foam formulation patents	May cover emulsion architecture, propellant system, performance or packaging
Method-of-use patents	May cover treatment of rosacea or other skin conditions
Manufacturing patents	May cover mixing, homogenization, filling or foam production
Device and package patents	Relevant to valves, actuators, canisters and metered delivery

The commercial barrier is therefore likely to be a combination of regulatory requirements, formulation know-how, manufacturing capability, and any unexpired formulation or package claims. A generic developer should not assume that expiry of an active-ingredient patent removes all product-specific risk.

When does Finacea lose exclusivity?

Finacea has no meaningful current new chemical entity exclusivity position because azelaic acid was approved and marketed well before the current commercial period. The gel and foam products entered the market at different times, and their regulatory exclusivity periods were separate from any patent protection.

Exclusivity type	Finacea relevance
NCE exclusivity	Expired or not commercially relevant
Orphan-drug exclusivity	Not applicable to the rosacea indication
Pediatric exclusivity	No material current barrier identified
Reference-product exclusivity	Historical relevance only for older approvals
Patent exclusivity	Product- and claim-specific; must be assessed by dosage form and jurisdiction
Regulatory exclusivity for generic entry	Generally less significant than formulation and patent analysis

For business planning, the relevant question is not whether azelaic acid remains protected. It is whether a proposed generic or follow-on product can satisfy FDA requirements for the selected dosage form without infringing valid product-specific claims.

What is the Orange Book status of Finacea?

The FDA Orange Book is the controlling source for current U.S. patent and exclusivity listings. Finacea Gel and Finacea Foam must be assessed as separate reference products because they have different approval histories, formulations, and delivery systems.

An Orange Book review should identify:

• The relevant NDA number for each product.
• Listed patents and their expiration dates.
• Whether any patent is formulation, method-of-use, or device-related.
• Whether a patent has a pediatric extension.
• Whether a proposed ANDA requires a Paragraph IV certification.
• Whether listed method-of-use patents can be carved out through a section viii statement.

For a gel product, the regulatory pathway is generally more predictable because the dosage form is a conventional semisolid. For a foam, the applicant must address formulation and device performance in greater depth. The absence of a current exclusivity barrier does not eliminate the possibility of a Paragraph IV dispute.

Which companies are challenging Finacea?

Publicly visible competition is likely to come from several groups:

Competitor group	Strategy
Generic dermatology companies	ANDA products that match the gel or foam reference product
Contract development and manufacturing organizations	Formulation development, scale-up and filling services
Specialty dermatology companies	Differentiated azelaic acid products for rosacea or acne
Cosmetic brands	Lower-strength azelaic acid products, usually outside the prescription pathway
International pharmaceutical companies	Creams, gels and combination products in non-U.S. markets

The most plausible ANDA competition is for the gel. Foam competition is more difficult because the applicant must solve both pharmaceutical equivalence and device-linked performance. Companies with aerosol filling, emulsion processing, and topical manufacturing capabilities have a structural advantage.

What Paragraph IV risks exist for Finacea?

Paragraph IV risk depends on the current Orange Book listing and the specific product being developed. A generic applicant may face several possible outcomes:

Scenario	Commercial effect
No unexpired listed patent	Earlier launch subject to FDA approval and market conditions
Paragraph IV certification	Litigation risk and possible 30-month stay
Section viii carve-out	Potential launch for non-patented indications or uses
Formulation patent dispute	Risk concentrated in the vehicle and process
Device or package patent dispute	Higher relevance for foam products
Settlement agreement	Launch may occur before full patent expiry under negotiated terms

A gel applicant may have more opportunities to design around formulation claims by using alternative polymers, surfactants, or emollients. A foam applicant has fewer easy design-around options because changes to the propellant, emulsion, valve, or canister can affect product performance.

What commercial opportunities exist for Finacea excipients?

The opportunity extends beyond a conventional generic.

1. Generic gel platform

A well-controlled azelaic acid gel can support products for rosacea and, subject to regulatory strategy, acne or pigmentation indications. Suppliers can compete through carbomer grades, preservative systems, skin-compatible humectants, and low-residue emollient blends.

2. Foam delivery platform

The foam format offers a higher-value opportunity because it is more difficult to reproduce and can support premium positioning. Opportunities include:

• Improved cold-temperature discharge.
• Lower residue after application.
• Better dose uniformity.
• Reduced irritation.
• Nonflammable or lower-impact propellant systems where technically and regulatorily viable.
• Alternative package formats with improved recyclability.

Any propellant change would require substantial performance and safety work. It is not a routine excipient substitution.

3. Combination products

Azelaic acid may be paired with other dermatologic actives in future prescription products, including agents used for acne, pigmentary disorders, or rosacea. Combination products create a new regulatory pathway and cannot rely automatically on Finacea’s approval history.

4. Private-label and cosmetic products

Lower-strength azelaic acid products have commercial potential in cosmetic and quasi-drug markets, depending on jurisdiction. These products can use simpler gels, creams, suspensions, or serums. The main commercial risks are ingredient stability, consumer tolerability, substantiation of claims, and regulatory classification.

5. Global formulation adaptation

Regional markets may favor creams rather than foams. A single azelaic acid platform can be adapted to local preferences through changes in viscosity, occlusivity, fragrance-free sensory design, package format, and climate stability. Geographic expansion can be more attractive in markets where prescription topical competition is limited.

How strong is the Finacea patent estate?

The patent estate is best characterized as moderate for formulation and delivery-system risk but weak for active-ingredient exclusivity. The gel has a lower technical barrier to entry because it uses a conventional topical vehicle. The foam has a stronger practical barrier because successful replication requires formulation, packaging, and manufacturing integration.

Factor	Gel assessment	Foam assessment
Active ingredient protection	Low	Low
Formulation complexity	Moderate	High
Excipient design-around potential	High	Moderate
Device dependence	Low	High
Manufacturing barrier	Moderate	High
Generic development cost	Lower	Higher
Differentiation opportunity	Moderate	High
Litigation exposure	Claim-specific	Claim- and device-specific

The strongest defensible position for a follow-on product is likely to come from a proprietary vehicle, manufacturing process, package, or clinical use rather than from azelaic acid itself.

What revenue exposure does Finacea create for competitors?

Finacea revenue exposure is concentrated in prescription rosacea treatment, while broader azelaic acid demand spans acne, hyperpigmentation, and cosmetic skincare. The commercial value of a generic launch depends on:

• The size of the U.S. rosacea market.
• The percentage of patients receiving topical therapy.
• Brand retention and prescriber loyalty.
• The number and timing of generic entrants.
• Whether the entrant launches gel, foam, or both.
• Wholesale acquisition price erosion.
• Payer formulary placement.
• Manufacturing capacity and supply reliability.

The first approved generic may capture meaningful value if it enters before multiple competitors. Later entrants generally face rapid price compression. A differentiated foam or better-tolerated gel can preserve margin more effectively than an undifferentiated commodity product.

Key Takeaways

• Finacea is a 15% azelaic acid prescription product available as a gel and foam.
• The active ingredient has little current exclusivity value; the commercial opportunity is in formulation, delivery, packaging, and manufacturing.
• Finacea Gel is the more accessible generic target.
• Finacea Foam has higher technical and manufacturing barriers because the formulation and container-closure system must work together.
• Key excipient opportunities include rheology modifiers, humectants, surfactants, emollients, preservatives, propellants, and package-compatible foam systems.
• Paragraph IV risk is product-specific and depends on current Orange Book listings and unexpired claims.
• Biosimilar risk is not relevant because azelaic acid is a small-molecule active ingredient.
• The most valuable follow-on strategies are differentiated vehicles, improved tolerability, better sensory performance, and scalable manufacturing.

FAQs

Is azelaic acid an active pharmaceutical ingredient or an excipient?

Azelaic acid is the active pharmaceutical ingredient in Finacea. It is not an excipient in the prescription product.

Can a generic Finacea product use different excipients?

Yes, a generic product may use different excipients if it satisfies applicable FDA requirements for pharmaceutical equivalence, product quality, safety, effectiveness, and performance.

Is Finacea Foam harder to manufacture than Finacea Gel?

Yes. Foam production requires control of emulsion structure, propellant, valve, actuator, container pressure, discharge, and in-use performance.

Does Finacea have biosimilar competition?

No. Biosimilar regulation applies to biologic products. Azelaic acid products are regulated as small-molecule drug products.

Can azelaic acid be developed as an over-the-counter product?

Lower-strength azelaic acid products may be marketed as cosmetics or other nonprescription products depending on jurisdiction and claims. A product making drug claims must satisfy the applicable regulatory pathway.

References

1. U.S. Food and Drug Administration. (2023a). Finacea (azelaic acid) gel, 15% prescribing information.
2. U.S. Food and Drug Administration. (2023b). Finacea (azelaic acid) foam, 15% prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs.
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.